Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer

Trial Profile

Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms PRODIGE 9
  • Most Recent Events

    • 12 Sep 2017 Results assessing factors that predict early progression during induction chemotherapy and chemotherapy-free interval duration presented at the 42nd European Society for Medical Oncology Congress
    • 06 Jun 2017 Results (n=230) of a computed analysis to build and validate a radiomics signature able to predict early the lack of response to chemotherapy presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 27 May 2016 Planned End Date changed from 1 Jul 2015 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top